e-learning
resources
Amsterdam 2015
Monday, 28.09.2015
IPF: from bench to bedside
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Effect of nintedanib on the release of angiogenic/angiostatic cytokines by alveolar macrophages (AMs) in interstitial lung diseases (ILD)
Xiaoping Long (Essen, Germany), Xiaoping Long, Ulrich Costabel, Xuan He, Thomas E. Wessendorf, Dirk Theegarten, Josune Guzman, Francesco Bonella
Source:
International Congress 2015 – IPF: from bench to bedside
Session:
IPF: from bench to bedside
Session type:
Poster Discussion
Number:
3054
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Xiaoping Long (Essen, Germany), Xiaoping Long, Ulrich Costabel, Xuan He, Thomas E. Wessendorf, Dirk Theegarten, Josune Guzman, Francesco Bonella. Effect of nintedanib on the release of angiogenic/angiostatic cytokines by alveolar macrophages (AMs) in interstitial lung diseases (ILD). Eur Respir J 2015; 46: Suppl. 59, 3054
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Management of severe community acquired pneumonia – ERS guidelines
Panel discussion on genetics in pulmonary fibrosis
Related content which might interest you:
Effect of pirfenidone (PFD) on cytokine/chemokine release from alveolar macrophages (AMs) in interstitial lung diseases (ILD): Preliminary results
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
Pirfenidone suppresses proinflammatory and antiangiogenetic cytokine production by alveolar macrophages (AMs) in idiopathic non specific interstitial pneumonia (iNSIP)
Source: International Congress 2014 – ILDs 2
Year: 2014
Thalidomide reduces IL-18, IL-8 and TNF-α release from alveolar macrophages in interstitial lung disease
Source: Eur Respir J 2006 Oct 01;28(4):824-831
Year: 2006
Circulating monocytes from interstitial lung disease patients show an activated phenotype
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016
Inhibition of profibrotic signaling in fibroblasts from patients with idiopathic pulmonary fibrosis (IPF) by histone deacetylase-inhibitors (HDACi) or the IPF drug pirfenidone
Source: International Congress 2014 – ILDs 1
Year: 2014
Effect of cigarette smoking on alveolar macrophages (AM) and lymphocytes (AL) apoptosis in selected interstitial lung diseases (ILD)
Source: Annual Congress 2008 - Role of bronchoalveolar lavage in studying the pathophysiology of interstitial lung disease
Year: 2008
Inhaled sargramostim and whole lung lavage (WLL) as therapy of autoimmune pulmonary alveolar proteinosis (aPAP)
Source: International Congress 2016 – Orphan diseases I
Year: 2016
Role of macrophage activation in type II alveolar cells transplantation for the treatment of idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Translational studies in chronic repair and remodelling in the lung
Year: 2013
Alveolar lymphocytes (AL) apoptosis in interstitial lung diseases (ILD). Increased AL apoptosis rate in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2009 - Pathogenesis of pulmonary fibrosis
Year: 2009
Uncoupling the pro-fibrotic effects of TGF-beta1 versus tissue hardening in lung fibroblasts
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
The effect of nintedanib compared to pirfenidone on proliferation of lung fibroblasts from patients with IPF
Source: International Congress 2015 – Interstitial lung diseases II
Year: 2015
Nintedanib prevents IL-1beta-stimulated proliferation of primary human lung fibroblasts from patients with idiopathic pulmonary fibrosis or from control donors
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014
Effect of nintedanib, pirfenidone, N-acetylcysteine and their combinations on cultured myofibroblast-type cells derived from patients with asbestosis and idiopathic pulmonary fibrosis
Source: International Congress 2015 – Airway remodelling: recent developments
Year: 2015
The role of macrophages in interstitial lung diseases
Source: Eur Respir Rev, 26 (145) 170009; 10.1183/16000617.0009-2017
Year: 2017
SMAD2 mRNA expression is upregulated in fibrosing interstitial lung diseases (ILDs)
Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease
Year: 2015
Whole lung lavage efficacy in pulmonary alveolar proteinosis (PAP) is influenced by the infusion volume?
Source: International Congress 2015 – IIPs: orphan
Year: 2015
Reduced anti-oxidant and increased inflammatory status in interstitial lung diseases (ILD)
Source: Eur Respir J 2007; 30: Suppl. 51, 110s
Year: 2007
M2 polarized alveolar macrophages in pulmonary fibrosis
Source: Annual Congress 2005 - Pulmonary hypertension and fibrosis: novel mechanisms
Year: 2005
Pulmonary alveolar proteinosis (PAP) in exogenous toxic alveolitis (ETA) patients
Source: International Congress 2015 – Occupational disease: clinical cases and series
Year: 2015
A mechanism for acceleration of GM-CSF autoantibody (GMAb) production in autoimmune pulmonary alveolar proteinosis (aPAP)
Source: International Congress 2014 – Molecular pathogenesis of pulmonary inflammatory diseases (COPD, asthma and ILD)
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept